Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

NCT00866320 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

DRUG: sorafenib tosylate

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]